Effect of Shufeiya Prescription on Pulmonary Artery Systolic Pressure and Quality of Life in Patients with Pulmonary Hypertension

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100004860

Enrollment

Unknown

Registered

2021-05-18

Start date

2021-06-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Interventions

Control group:Placebo

Treatment group:Shufeiya prescription

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 80 years, gender is not limited; 2.Meets the diagnostic standard of pulmonary hypertension; 3.Patients with fixed dose and type of conventional medicine last month; 4.Patients who did not receive targeted drug therapy or targeted drug therapy regimen fixed for at least a month; 5.Patients who had not received interventional or surgical treatment within 6 months before the trial; 6.Volunteer to participate in the clinical trial, understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with acute exacerbation of chronic heart failure, acute myocardial infarction, coronary revascularization, and cardiac resynchronization within a month before the trial; 2.Patients with acute exacerbation of COPD/combined pulmonary infection within a month before the trial; 3.Patients with right ventricular outflow tract obstruction; 4.Patients with malignant tumors, mental disorders, malignant arrhythmias and other serious diseases; 5.Patients with severe renal disease (serum creatinine > 450umol/L) or liver disease (including serum transaminase >3 times the upper limit of normal value); 6.Patients who had taken Chinese medicine preparations (including TCM decoction pieces, granules, Proprietary Chinese medicine, TCM intravenous preparations, etc.) within 2 weeks before the trial; 7.Patients with disadvantageous activities of lower limbs and unable to cooperate with the completion of relevant examinations; 8.Pregnant women and lactating women; 9.Patients with known allergy to the drug ingredients and excipients in this trial.

Design outcomes

Primary

Measure	Time frame
Pulmonary artery systolic pressure;	—

Secondary

Measure	Time frame
Ultrasonic cardiogram;Six minutes walking distance;Endothelin - 1;WHO functional class;Quality of Life Scale;Nitric oxide;Borg dyspnea scores;	—

Countries

China

Contacts

Public ContactMao Jingyuan

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

jymao@126.com+86 13820498886

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026